Literature DB >> 27806848

A comparison of cancer stem cell markers and nonclassical major histocompatibility complex antigens in colorectal tumor and noncancerous tissues.

Rabia Bilge Özgül Özdemir1, Alper Tunga Özdemir2, Fatih Oltulu3, Kamile Kurt4, Gürkan Yiğittürk3, Cengiz Kırmaz5.   

Abstract

Colorectal carcinoma (CRC) is one of the most fatal types of cancer in both women and men, and, unfortunately, patients are often diagnosed at an advanced stage. Cancer stem cells (CSCs) are associated with poor prognosis, metastasis, and recurrence, as well as chemotherapy and radiotherapy resistance. Therefore, different treatment alternatives are needed to facilitate the elimination of CSCs. One such approach is immunotherapy; however, tumor cells can evade immune cells by alteration of the expression patterns of human leukocyte antigens (HLA). In this study, we immunohistochemically investigated the expression patterns of CSC-specific markers CD44, CD133, Nanog, and Oct3/4, and immunosuppressive molecules HLA-G and -E in advanced CRC tumor tissues and noncancerous colon biopsies. We found significantly increased CD44, Nanog, Oct3/4, HLA-G, and HLA-E expression in the CRC tumor tissues compared with the noncancerous colon biopsies. These findings suggest that some tumor cells may be CSC-like and that the increased expression of HLA-G and HLA-E may be considered as an immune-evasive adaptation. Therefore, the nonclassical major histocompatibility complex class Ib antigens HLA-G and HLA-E may be potential targets in the elimination of CRC-CSCs. However, more detailed studies are required to support our findings.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD133; CD44; Colorectal cancer; HLA-E; HLA-G; Nanog; Oct3/4

Mesh:

Substances:

Year:  2016        PMID: 27806848     DOI: 10.1016/j.anndiagpath.2016.09.012

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  7 in total

1.  Glucose-Regulated Protein 94 Mediates the Proliferation and Metastasis through the Regulation of ETV1 and MAPK Pathway in Colorectal Cancer.

Authors:  Uyanga Batzorig; Po-Li Wei; Weu Wang; Chien-Yu Huang; Yu-Jia Chang
Journal:  Int J Med Sci       Date:  2021-03-27       Impact factor: 3.738

2.  Therapeutic strategies against cancer stem cells in human colorectal cancer.

Authors:  Magdalena Szaryńska; Agata Olejniczak; Jarosław Kobiela; Piotr Spychalski; Zbigniew Kmieć
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

Review 3.  Dimorphism of HLA-E and its Disease Association.

Authors:  Leonid Kanevskiy; Sofya Erokhina; Polina Kobyzeva; Maria Streltsova; Alexander Sapozhnikov; Elena Kovalenko
Journal:  Int J Mol Sci       Date:  2019-11-04       Impact factor: 5.923

Review 4.  Role of immune escape in different digestive tumours.

Authors:  Xin-Zhu Du; Bin Wen; Lin Liu; Ying-Ting Wei; Kui Zhao
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

Review 5.  Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy.

Authors:  Hassan Dianat-Moghadam; Amir Mahari; Reza Salahlou; Mostafa Khalili; Mehdi Azizi; Hadi Sadeghzadeh
Journal:  Stem Cell Res Ther       Date:  2022-04-08       Impact factor: 6.832

Review 6.  Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications.

Authors:  Ioannis A Voutsadakis
Journal:  Cell Oncol (Dordr)       Date:  2018-02-22       Impact factor: 6.730

Review 7.  Cancer stem cells in progression of colorectal cancer.

Authors:  Yujuan Zhou; Longzheng Xia; Heran Wang; Linda Oyang; Min Su; Qiang Liu; Jingguan Lin; Shiming Tan; Yutong Tian; Qianjin Liao; Deliang Cao
Journal:  Oncotarget       Date:  2017-12-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.